Intelligent Bio Solutions reported preliminary, unaudited revenue for fiscal Q1 2026 (ended September 30, 2025) of $1.04 million, up 32 % sequentially and 28 % year‑over‑year.
Cartridge revenue rose 43 % year‑over‑year to $0.68 million, while reader revenue increased 23 % year‑over‑year to $0.36 million. The shift toward consumables has expanded gross margin.
Prior‑period comparisons show Q4 2025 revenue of $843,884 and Q1 2025 revenue of $870,000. Net loss for Q1 2025 was $2.70 million. The company added 33 new customer accounts, bringing total active accounts to over 480.
The company is progressing toward FDA 510(k) clearance for its drug‑screening system, and the global drug‑screening market is projected to reach $17.1 billion by 2029. Management expects to file the full Form 10‑Q during the week of November 10, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.